Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Alto crecimiento de los beneficios
Los ingresos netos de la empresa lideran el sector. Sus ingresos anuales más recientes ascienden a 172.35M USD.
Infravalorada
El PE más reciente de la empresa es -7.48, en un rango percentil bajo de 3 años.
Venta institucional
Las tenencias institucionales más recientes son 109.02M acciones, lo que supone una reducción del 9.40% con respecto al trimestre anterior.
En posesión de Steven Cohen
El inversor estrella Steven Cohen posee 2.37M acciones de este valor.
Mayor actividad del mercado
La empresa está generando mayor interés entre los inversores, con una relación de rotación de 20 días del 0.21.